The ubiquitous danger of substandard medicines

Shehzad Noorani/World Bank

Women working at GK Pharmaceutical Company in Bangladesh.

Article Highlights

  • Drugs are legally and poorly produced, which could lead to deadly results

    Tweet This

  • Recent study: More than 12% of drugs produced in emerging markets failed quality tests

    Tweet This

  • Counterfeit drug problem worse for emerging markets targeting home countries

    Tweet This

Dangerous medicines are a global problem. Increasing media attention focuses on the threat of counterfeit or falsified products which are intentionally made to deceive the patient. While counterfeits must be combated, drugs that are legally but poorly produced, substandard medicines-the subject of today's briefing-tend to get a free pass, even when they kill.

Demand for pharmaceuticals in mid-income and developing countries is increasing rapidly. Internationally-traded generic drugs, most commonly from India, not only have entered these markets, but tend to dominate them. Recently, many nations-sometimes supported by western aid agencies-have begun to develop their own pharmaceutical production capabilities.

In principle, expanded drug production is good for consumers, since increased competition will cause prices to fall, thereby increasing drug access and, ultimately, patients' welfare. Increased access to cheap products is only beneficial to the patient, however, if the products are "bioequivalent" (act in the same way in the body) to the approved products which they are copying.

"The worst offenders were domestic pharmaceutical manufacturers in Africa, followed by smaller producers in India, and all producers from China and Vietnam."--Roger Bate

What is a substandard drug?

Substandard drugs are medicines which are made by a licensed manufacturer supposedly adhering to pharmaceutical regulatory standards, but nevertheless fail to produce the correct therapeutic effect in the patient. This can be due to a variety of causes, including basic errors such as incorrect chemical ingredients or ingredient ratios. Repeated empirical studies revealed many errors of this type[1]. More complicated problems, which our analysis (published in a recent paper in the journal Pharmacologia[2] could not detect, include tiny, but potentially lethal, impurities and poorly chosen excipients (inert fillers and dyes) which prevent the active ingredient from releasing as planned in the body. These errors are caused by shoddy production and poor oversight of the often intricate formulation process.

Emerging Markets

In our analysis of over two thousand antibacterial and antimalarial drugs procured in 19 cities in emerging markets, we found that more than 4% (subsequent analysis shows it's more like 5%) of the legal products on sale were substandard (over 12% failed quality tests, but the majority of these were obviously degraded or counterfeit). The worst offenders were domestic pharmaceutical manufacturers in Africa, followed by smaller producers in India, and all producers from China and Vietnam. Products from large Indian, European, and American producers were consistently high quality.

India provides some insight into the factors which contribute to good production. Larger Indian companies performed better than the smaller ones, but it is perhaps more relevant that the best performing companies came from two states, Maharastra and Andra Pradesh[3]. Experts agree that these states enforce good manufacturing practices (GMP), whereas other Indian states are less diligent. It is unclear whether tougher regulation drives better performance, or better performing companies demand better regulation as a barrier to entry, but either way, overall quality is better.

All companies can make mistakes, but following GMP should ensure that company systems catch basic errors. Widespread and substantial production errors found in the sample below demonstrate that many emerging market producers simply do not follow GMP.

For example, China reputedly produces many, perhaps most, of the world's fake drugs[4], and allows sloppy production which has killed an indeterminate number of people[5]. It is not surprising, then, that approximately 5% of its legitimate products had significant quality problems. These oversight problems are dangerous not only to Chinese consumers, but to patients around the globe. Most of the world now purchases chemical inputs, including active pharmaceutical ingredients (API) from China; such slip ups and poor oversight of GMP means unwary producers, both inside and outside of China, may be receiving suspect API[6].

Our data also suggests that the problem is worse in emerging market companies targeting their home market. Domestic products failed quality tests more often than their internationally traded counterparts. We conclude that low quality standards and lack of GMP enforcement needs to be addressed by companies and governments in the developing world-but protection of local industries is a nontrivial problem, and one I suspect means substandard drugs will be hard to address.

As a result, donors must not just undertake one off product surveillance, but must ensure continuous and random post marketing surveillance of the products they buy-since some companies have shown themselves to be able to produce a good product, but not consistently deliver that high quality product to the market.

Roger Bate is the Legatum Fellow in Global Prosperity at AEI

Footnotes

1. Roger Bate, L Mooney and K Hess. "Medicine Registration and Medicine Quality: A Preliminary Analysis of Key Cities in Emerging Markets." Research and Reports in Tropical Medicine. 2010:1, 89-93 (Dec 2010). DOI: 10.2147/RRTM.S15199

2. Roger Bate, J Milligan and L Mooney, "The Danger of Substandard Drugs in Emerging Markets: An Assessment of Basic Product Quality" Pharmacologia 3 (2012): 46–51

3. Bate et. al. "A Safe Medicine Chest for the World." International Policy Network (May 18 2010), available at http://www.policynetwork.net/sites/default/files/Safe_Medicines_Chest_2010.pdf.

4. "China’s Counterfeit Medicine Trade is booming." Canadian Medical Association Journal, (Nov 10 2009) 181, 10, available at http://www.cmaj.ca/cgi/content/full/181/10/E237.

5. One example is the fatal melamine contamination of milk, see "Chinese Milk Scam Duo Face Death," available at http://news.bbc.co.uk/2/hi/asia-pacific/7843972.stm

6. Office of the U.S. Trade Representative (USTR), "Special 301 Report," (2007) Available at: http://www.ustr.gov/sites/default/files/asset_upload_file230_11122.pdf Accessed 15 August 2010

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate

What's new on AEI

Love people, not pleasure
image Oval Office lacks resolve on Ukraine
image Middle East Morass: A public opinion rundown of Iraq, Iran, and more
image Verizon's Inspire Her Mind ad and the facts they didn't tell you
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Monday, July 21, 2014 | 9:15 a.m. – 11:30 a.m.
Closing the gaps in health outcomes: Alternative paths forward

Please join us for a broader exploration of targeted interventions that provide real promise for reducing health disparities, limiting or delaying the onset of chronic health conditions, and improving the performance of the US health care system.

Monday, July 21, 2014 | 4:00 p.m. – 5:30 p.m.
Comprehending comprehensive universities

Join us for a panel discussion that seeks to comprehend the comprehensives and to determine the role these schools play in the nation’s college completion agenda.

Tuesday, July 22, 2014 | 8:50 a.m. – 12:00 p.m.
Who governs the Internet? A conversation on securing the multistakeholder process

Please join AEI’s Center for Internet, Communications, and Technology Policy for a conference to address key steps we can take, as members of the global community, to maintain a free Internet.

Event Registration is Closed
Thursday, July 24, 2014 | 9:00 a.m. – 10:00 a.m.
Expanding opportunity in America: A conversation with House Budget Committee Chairman Paul Ryan

Please join us as House Budget Committee Chairman Paul Ryan (R-WI) unveils a new set of policy reforms aimed at reducing poverty and increasing upward mobility throughout America.

Thursday, July 24, 2014 | 6:00 p.m. – 7:15 p.m.
Is it time to end the Export-Import Bank?

We welcome you to join us at AEI as POLITICO’s Ben White moderates a lively debate between Tim Carney, one of the bank’s fiercest critics, and Tony Fratto, one of the agency’s staunchest defenders.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.